Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer

E-ISSN： 1875-533x|23|7|636-649

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.7, 2016-02, pp. : 636-649

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer

Mini Reviews in Medicinal Chemistry, Vol. 16, Iss. 2, 2016-01 ,pp. : 86-93

Bentham Science Publishers

Access to resources Recommend Favorite

Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?

Current Cancer Drug Targets, Vol. 13, Iss. 4, 2013-01 ,pp. : 460-471

Bentham Science Publishers

Access to resources Recommend Favorite

Saxagliptin overview: special focus on safety and adverse effects

By Ali Shamsa Fonseca Vivian

Expert Opinion on Drug Safety, Vol. 12, Iss. 1, 2013-01 ,pp. : 103-109

Informa Healthcare

Access to resources Recommend Favorite

New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPAR&ggr; Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy

Current Cancer Drug Targets, Vol. 5, Iss. 6, 2005-09 ,pp. : 393-419

Bentham Science Publishers

Access to resources Recommend Favorite

Interview: An interview with Pharmacogenomics for the breast cancer special focus issue

By Weinshilboum Richard M

Pharmacogenomics, Vol. 13, Iss. 6, 2012-04 ,pp. : 655-658

Future Medicine

Access to resources Recommend Favorite